What is INCY's 12-month stock price target?

Incyte Corp. (INCY) carries a 12-month consensus base price target of $136.25 (+13.5% from $120.04), with a bull-case target of $160.78 and a bear-case floor of $98.43.

Stock Ratings / Health Care / INCY / forecast

MEDP (77) CRL (64) ICLR (72) IQV (61) ⌘ Pro Terminal →

Incyte Corp. (INCY) 12-Month Stock Forecast & Price Target Cone

Q: Is INCY stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates INCY A (Strong Buy — BUY) with an RQD Confidence score of 88/100.

$120.04 -0.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $120.27

Incyte Corp. (INCY) earns a Roarable Rating of A (Strong Buy) with 88/100 RQD Confidence. High-quality cash engine (92.8% gross margin, 42% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE A • STRONG BUY Cap $24.54B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INCY Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INCY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Incyte Corp. (NASDAQ: INCY) is rated A (Strong Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 88/100 at a spot price of $120.04 (-0.29% 1D, market cap $24.54B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 17/20, and Executive Insider Alignment 18/20. Across 1015 tracked Health Care issuers, INCY ranks #2 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INCY compare to MEDP and CRL in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), INCY carries a Roarable A (88/100 RQD), trailing P/E of 18.4x, gross margin of 92.8%, and ROIC of 42.4%. By comparison, MEDP (Medpace Holdings Inc.) holds a B+ grade (77/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.24B) and CRL (Charles River Laboratories International Inc.) posts a C grade (64/100 RQD, P/E N/A, ROIC 0.4%, cap $17.16B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INCY?

▼

Per INCY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000879169), Incyte Corp. generated $5.14B in revenue (+21.2% YoY), $1.29B in net income, and $1.18B in free cash flow against $6.96B in total assets and $805.7M in total debt. Key quantitative strengths: Strong cash generator (92.8% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $120.27 (+0.19%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 23% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 88/100 (A) historically ranked in the Top 4% of excess returns over the next 90 days (+9.5% avg 90D alpha vs SPY • 73.8% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSTRONG BUY • A

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A · Rk A

Each axis scored 0–20

12M PRICE TARGET CONE+13.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INCY)Realized 20D OHLCV Swing Band: ±6.1%

Deterministic 5-Pillar Attribution (88/100 Composite)

🔍 WHY INCY SCORES 88/100 (A) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 23% FCF Margin ($1.18B FCF) & 92.8% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (20% of score)

Altman Z-Score 10.04 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning16/20 pts (-4 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-4 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A-$111.57+1.7% Next Q

Q2 (-2Q)

Grade A$113.44+3% Next Q

Q3 (-1Q)

Grade A$116.87+2.7% Next Q

Current

Grade A$120.04+9.5% Hist 90D α

Trajectory: A- (80) → A (88)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the INCY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 88/100 (A) score, INCY faces multiple-compression risk if 18.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 90.3% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($119.86) or 200D SMA ($108.26) invalidates the momentum regime and cuts Target Base ($136.25) toward Bear Floor ($98.43).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INCY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INCY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 88%NO 12%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your INCY Position Size: $10,000

Shares at $120.04: 83.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $98.43

$8,200

$-1,800 (-18.0%)

12M Consensus BaseTarget $136.25

$11,350

+$1,350 (+13.5%)

12M Bull Case BreakoutTarget $160.78

$13,394

+$3,394 (+33.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (43 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 32● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	OUTPERFORM	$142	74%	A
Goldman SachsSector Coverage Lead	STRONG BUY	$151	69%	B
JP MorganUS Large-Cap Research	HOLD	$117	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (INCY Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INCY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.57%▼ DESCENDING CHANNEL

2026-11-03O $116.8H $120.4L $116.8C $120.0VOL 2.84M

RES: $125.3SUP: $105.1SMA50: $119.9SMA200: $108.3

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INCY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INCY Butterfly Map → + Track INCY →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

11.7%/yr Implied 5Y Growth

vs. +21.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on INCY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INCY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INCY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INCY)

Health Care Rank #2 of 1015 ⚔️ MEDP vs INCY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INCY vs. MEDP, CRL, ICLR, IQV)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Incyte Corp. (INCY) ranks #2 by composite RQD confidence (88/100, grade A) and #64 by equity capitalization ($24.54B). Within this direct 5-issuer industry benchmark cohort, INCY leads on earnings valuation at 18.4x trailing P/E, while INCY leads on capital efficiency and profitability with 42.4% ROIC and 92.8% gross margin. INCY currently leads its immediate peer cohort in composite quantitative strength at 88/100 (A).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INCY ACTIVE Incyte Corp.	A	88/100	18.4x	92.8%	42.4%	-0.29%	$24.54B	Benchmark Subject
MEDP Medpace Holdings Inc.	B+	77/100	42.0x	—	27.9%	-0.59%	$18.24B	/medp-vs-incy →
CRL Charles River Laboratories International Inc.	C	64/100	—	—	0.4%	-5.81%	$17.16B	/crl-vs-incy →
ICLR ICON plc	B	72/100	71.9x	—	3.1%	-2.94%	$16.18B	/iclr-vs-incy →
IQV IQVIA Holdings Inc.	C-	61/100	33.3x	—	9.4%	-3.32%	$44.06B	/iqv-vs-incy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000879169 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Incyte Corp. (INCY) reported GAAP revenue of $5.14B (+21.2% vs. FY2024 revenue of $4.24B , and +39.1% cumulative change since FY2023) , GAAP net income of $1.29B, operating cash flow of $1.41B, and free cash flow of $1.18B (+718.2% YoY). On the balance sheet, INCY closed FY2025 with $6.96B in total assets against $805.7M in total debt (Altman Z-Score: 10.04, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$5.14B	$1.29B	$1.41B	$1.18B	$6.96B	$805.7M
FY2024 (FY)	2024-12-31	$4.24B	$32.6M	$335.3M	$144.5M	$5.44B	$898.5M
FY2023 (FY)	2023-12-31	$3.70B	$597.6M	$496.5M	$330.2M	$13.02B	$3.05B

3. INCY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INCY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does INCY compare to MEDP and CRL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for INCY?

Where is INCY trading relative to its 50-day, 200-day, and 52-week technical levels?

INCY last traded at $120.04 (-0.29% on volume of 1,748,404 shares), positioning the stock +0.15% above its 50-day simple moving average ($119.86) and +10.88% above its 200-day simple moving average ($108.26). Across its 52-week range of $89.25 to $132.60, INCY sits at the 71.0% percentile with a 14-day RSI of 56.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.1% ($112.72 to $127.36).

Direct Sub-Reports: INCY RQD Cockpit INCY 12M Forecast INCY Earnings & Move INCY Dividends & DRIP INCY Insiders & 13F INCY Whale Options INCY Profit Sankey INCY News & Why

ROARABLE RATING BRIEF • RQD 88/100 (A) ✓ SEC XBRL & RQD VERIFIED

INCY — Incyte Corp.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Incyte Corp. (INCY) earns a live Roarable RQD composite score of 88/100, corresponding to a A letter grade (Roarable Strong Buy) at a spot price of $120.04 (-0.29% 1D, market capitalization $24.54B).

Fundamental Cash Engine (19/20): Anchored by return on invested capital (ROIC) of 42.4%, gross margin of 92.8%, operating margin of 29.5%, and free cash flow yield of 4.99%.
Whale 13F & Options Flow (16/20) + Insider Conviction (18/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (17/20) + Forensic Balance Sheet (18/20): Incorporates a 1.01x equity beta, Altman Z-Score of 10.04, Piotroski F-Score of 9/9, and Debt/Equity of 0.15x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Incyte Corp. (INCY) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Commercial Physical & Biological Research industry. The profile places its market capitalization at $23.7B. The gross margin is 92.8% and the operating margin is 29.5%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Incyte Corp. (INCY) reported $5.14B in annual revenue (up from $4.24B in FY2024, +21.2% YoY) and $1.29B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.70B revenue, $597.6M net income) through FY2025, INCY scaled operating cash flow to $1.41B and free cash flow to $1.18B, backed by $6.96B in total assets against $805.7M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (A • RQD 88/100): Strong cash generator (92.8% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 19/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $89.25 – $132.60 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 18.4x trailing P/E and 12.5x EV/EBITDA against 29.5% operating margins and a 1.01x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Commercial Physical & Biological Resarch (Health Care), INCY carries a macro regime beta of 1.01 and gross margin of 92.8%.

Key Question #1: Can INCY sustain or expand its 29.5% operating margin and 42.4% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $5.14B and free cash flow of $1.18B, how will capital allocation balance growth reinvestment against $805.7M in total debt?
Key Question #3: How sensitive is INCY's 15.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.01x)?

INCY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Incyte Corp. (INCY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INCY Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

Can Incyte Stock Hit $170?

Yahoo Finance report covering Incyte Corp. (INCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 1d ago

Stifel raises Incyte stock price target on pipeline potential

Investing.com report covering Incyte Corp. (INCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

If You Invested $1000 In Incyte Stock 15 Years Ago, You Would Have This Much Today

Benzinga report covering Incyte Corp. (INCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Is Incyte (INCY) Cheap After A 120% Three Year Run?

Yahoo Finance report covering Incyte Corp. (INCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

463 shares are automatically withheld for taxes from Incyte (INCY) EVP Lee Heeson at $117.14 each.

Stock Titan report covering Incyte Corp. (INCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Incyte (INCY) Unveils Fresh Oncology Data, Is The Stock 9% Undervalued?

Simply Wall St report covering Incyte Corp. (INCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Pluang • 1d ago

Incyte Corporation (INCY) Stock Price Today: $120.39

Pluang report covering Incyte Corp. (INCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

What to Expect From Incyte’s Next Quarterly Earnings Report

Yahoo Finance report covering Incyte Corp. (INCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INCY Bull vs. Bear Conversation Board — What's Your Call at $120.04?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INCY 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $148.08 (+23.0%)

📌 Pinned Debate

Per the Roarable RQD rating, a Fundamental Cash Engine score of 19/20 with ROIC of 42.4% and FCF yield of 4.99% signals strong cash gen

The street is overcomplicating Incyte Corp. (INCY). Per the Roarable RQD rating, a Fundamental Cash Engine score of 19/20 with ROIC of 42.4% and FCF yield of 4.99% signals strong cash generation.. With an RQD score of 88/100 (A) and Forensic Balance Sheet at 18/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $130.02.

EarningsSniper 🐂 BULL

@BearTrap_Alert Shorting a 16/20 institutional whale-flow stock at $120.39 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $90.29 (-25.0%)

Spot @ $120.39

Per the Roarable RQD rating, the Whale 13F Flow pillar scores only 12/20, indicating weaker institutional accumulation signals.

I respect the product at Incyte Corp., but the stock at $120.39 is a different story. Per the Roarable RQD rating, the Whale 13F Flow pillar scores only 12/20, indicating weaker institutional accumulation signals.. FCF yield is 4.99% and RQD sits at 88/100 (A) — why pay up here when you can wait for next quarter's numbers?